Predicting Venous Thromboembolic Events in Patients with Coronavirus Disease 2019 Requiring Hospitalization: an Observational Retrospective Study by the COVIDIC Initiative in a Swiss University Hospital.
Aged
Aged, 80 and over
Antifibrinolytic Agents
/ therapeutic use
COVID-19
/ blood
Female
Fibrin Fibrinogen Degradation Products
/ metabolism
Humans
Incidence
Male
Middle Aged
Multivariate Analysis
Pulmonary Embolism
/ drug therapy
Retrospective Studies
SARS-CoV-2
/ isolation & purification
Switzerland
/ epidemiology
Venous Thromboembolism
/ drug therapy
Venous Thrombosis
/ drug therapy
Journal
BioMed research international
ISSN: 2314-6141
Titre abrégé: Biomed Res Int
Pays: United States
ID NLM: 101600173
Informations de publication
Date de publication:
2020
2020
Historique:
received:
20
08
2020
revised:
04
10
2020
accepted:
10
10
2020
entrez:
18
11
2020
pubmed:
19
11
2020
medline:
15
12
2020
Statut:
epublish
Résumé
Coronavirus disease 2019 (COVID-19) can result in profound changes in blood coagulation. The aim of the study was to determine the incidence and predictors of venous thromboembolic events (VTE) among patients with COVID-19 requiring hospital admission. Among 443 patients with COVID-19, VTE was diagnosed in 41 patients (9.3%; 27 pulmonary embolisms, 12 deep vein thrombosis, one pulmonary embolism and deep vein thrombosis, one portal vein thrombosis). VTE was diagnosed already upon admission in 14 (34.1%) patients and 27 (65.9%) during hospital stay (18 in ICU and nine in wards outside the ICU). Multivariate analysis revealed D-dimer value > 3,120 ng/ml ( VTE seems to be a common COVID-19 complication upon admission and during hospitalization, especially in ICU. The combination of Wells ≥ 2 score and D - dimer ≥ 3,000 ng/l is a good predictor of VTE at admission.
Sections du résumé
BACKGROUND
BACKGROUND
Coronavirus disease 2019 (COVID-19) can result in profound changes in blood coagulation. The aim of the study was to determine the incidence and predictors of venous thromboembolic events (VTE) among patients with COVID-19 requiring hospital admission.
RESULTS
RESULTS
Among 443 patients with COVID-19, VTE was diagnosed in 41 patients (9.3%; 27 pulmonary embolisms, 12 deep vein thrombosis, one pulmonary embolism and deep vein thrombosis, one portal vein thrombosis). VTE was diagnosed already upon admission in 14 (34.1%) patients and 27 (65.9%) during hospital stay (18 in ICU and nine in wards outside the ICU). Multivariate analysis revealed D-dimer value > 3,120 ng/ml (
CONCLUSIONS
CONCLUSIONS
VTE seems to be a common COVID-19 complication upon admission and during hospitalization, especially in ICU. The combination of Wells ≥ 2 score and D - dimer ≥ 3,000 ng/l is a good predictor of VTE at admission.
Identifiants
pubmed: 33204727
doi: 10.1155/2020/9126148
pmc: PMC7656238
doi:
Substances chimiques
Antifibrinolytic Agents
0
Fibrin Fibrinogen Degradation Products
0
fibrin fragment D
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
9126148Informations de copyright
Copyright © 2020 Eleftheria Kampouri et al.
Déclaration de conflit d'intérêts
All authors state that they have no conflict of interest to report.
Références
Euro Surveill. 2020 Jan;25(3):
pubmed: 31992387
J Thromb Haemost. 2020 Apr;18(4):844-847
pubmed: 32073213
Int J Epidemiol. 2011 Jun;40(3):819-27
pubmed: 21324940
J Thromb Haemost. 2018 Feb;16(2):231-241
pubmed: 29193703
Rev Med Suisse. 2020 May 6;16(692):917-923
pubmed: 32374537
Ann Intern Med. 2020 Aug 18;173(4):268-277
pubmed: 32374815
Thromb Res. 2020 Dec;196:222-226
pubmed: 32916564
J Clin Med. 2020 Aug 03;9(8):
pubmed: 32756383
Circulation. 2003 Jun 17;107(23 Suppl 1):I9-16
pubmed: 12814980
Thromb Res. 2020 Jul;191:145-147
pubmed: 32291094
J Biomed Inform. 2019 Jul;95:103208
pubmed: 31078660
Clin Chem Lab Med. 2020 Jun 25;58(7):1116-1120
pubmed: 32172226
Respir Med Case Rep. 2019 Jun 14;28:100884
pubmed: 31245274
Blood. 2019 Feb 28;133(9):906-918
pubmed: 30642917
N Engl J Med. 2020 Apr 30;382(18):1708-1720
pubmed: 32109013
Lancet. 2020 Mar 28;395(10229):1054-1062
pubmed: 32171076
J Thromb Haemost. 2020 Jun;18(6):1421-1424
pubmed: 32271988
J Thromb Haemost. 2020 Jul;18(7):1743-1746
pubmed: 32320517
Clin Infect Dis. 2011 Jan 15;52(2):e14-7
pubmed: 21288835
Thromb Res. 2020 Nov;195:95-99
pubmed: 32682004
Intensive Care Med. 2020 Jun;46(6):1089-1098
pubmed: 32367170
Br J Haematol. 2019 Sep;186(5):792-793
pubmed: 31168834
Thromb Res. 2020 Jul;191:9-14
pubmed: 32353746
Eur Heart J. 2019 Nov 1;40(42):3453-3455
pubmed: 31697840
J Thromb Thrombolysis. 2020 Apr 3;:
pubmed: 32246317
J Thromb Haemost. 2020 Aug;18(8):1995-2002
pubmed: 32369666
Lancet. 2020 Feb 15;395(10223):497-506
pubmed: 31986264
Front Immunol. 2020 May 01;11:827
pubmed: 32425950
JAMA Intern Med. 2020 Jul 1;180(7):934-943
pubmed: 32167524
Circulation. 2012 May 1;125(17):2092-9
pubmed: 22474264
Radiology. 2020 Jun;295(3):715-721
pubmed: 32053470
Clin Exp Rheumatol. 2020 Mar-Apr;38(2):337-342
pubmed: 32202240